Why Pfizer Is Tapping Private Equity to Back Its Once-Monthly Weight-Loss Drug

Why Pfizer Is Tapping Private Equity to Back Its Once-Monthly Weight-Loss Drug

来源:Barrons发布于 2026-11-12

Blackstone Life Sciences agrees to pay $1.5 billion in development costs for Pfizer's berobenatide through 2028 in exchange for milestone-based payments.

相关标的:PFE

本文内容来自外部来源,点击「继续访问」将跳转到原始发布站点。